These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 38600789)

  • 1. Primary Care Providers' Experiences Treating Opioid Use Disorder Using Telehealth in the Height of the COVID-19 Pandemic.
    Marshall SA; Siebenmorgen LE; Youngen K; Borders T; Zaller N
    J Prim Care Community Health; 2024; 15():21501319241246359. PubMed ID: 38600789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic.
    Mattocks KM; Moore DT; Wischik DL; Lazar CM; Rosen MI
    J Subst Abuse Treat; 2022 Aug; 139():108777. PubMed ID: 35346533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
    Cales RH; Cales SC; Shreffler J; Huecker MR
    J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives.
    Aronowitz SV; Engel-Rebitzer E; Dolan A; Oyekanmi K; Mandell D; Meisel Z; South E; Lowenstein M
    Harm Reduct J; 2021 Nov; 18(1):119. PubMed ID: 34823538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient perceptions of and experiences with stigma using telehealth for opioid use disorder treatment: a qualitative analysis.
    Couch JV; Whitcomb M; Buchheit BM; Dorr DA; Malinoski DJ; Korthuis PT; Ono SS; Levander XA
    Harm Reduct J; 2024 Jun; 21(1):125. PubMed ID: 38937779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Telehealth for Opioid Use Disorder Treatment in Safety Net Primary Care Settings: A Mixed-Methods Study.
    Bailey SR; Wyte-Lake T; Lucas JA; Williams S; Cantone RE; Garvey BT; Hallock-Koppelman L; Angier H; Cohen DJ
    Subst Use Misuse; 2023; 58(9):1143-1151. PubMed ID: 37170596
    [No Abstract]   [Full Text] [Related]  

  • 7. Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic.
    Jones CM; Diallo MM; Vythilingam M; Schier JG; Eisenstat M; Compton WM
    Drug Alcohol Depend; 2021 Aug; 225():108783. PubMed ID: 34049102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine.
    Uscher-Pines L; Sousa J; Raja P; Mehrotra A; Barnett M; Huskamp HA
    J Subst Abuse Treat; 2020 Nov; 118():108124. PubMed ID: 32893047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinician Perspectives on Delivering Medication Treatment for Opioid Use Disorder during the COVID-19 Pandemic: A Qualitative Evaluation.
    Lott AM; Danner AN; Malte CA; Williams EC; Gordon AJ; Halvorson MA; Saxon AJ; Hagedorn HJ; Sayre GG; Hawkins EJ
    J Addict Med; 2023 Jul-Aug 01; 17(4):e262-e268. PubMed ID: 37579107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Red Flags' and 'Red Tape': Telehealth and pharmacy-level barriers to buprenorphine in the United States.
    Textor L; Ventricelli D; Aronowitz SV
    Int J Drug Policy; 2022 Jul; 105():103703. PubMed ID: 35561484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A qualitative study of patient experiences with telemedicine opioid use disorder treatment during COVID-19.
    Lockard R; Priest KC; Gregg J; Buchheit BM
    Subst Abus; 2022; 43(1):1150-1157. PubMed ID: 35499402
    [No Abstract]   [Full Text] [Related]  

  • 13. Experiences of Opioid Use Disorder Patients Receiving Buprenorphine Through a Telehealth Program.
    Moore DJ; Goyal D; Rodriguez L
    J Addict Nurs; 2021 Jul-Sep 01; 32(3):205-210. PubMed ID: 34473450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder.
    Lin LA; Zhang L; Kim HM; Frost MC
    Am J Psychiatry; 2022 Oct; 179(10):740-747. PubMed ID: 35899380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
    Hughes PM; Verrastro G; Fusco CW; Wilson CG; Ostrach B
    J Rural Health; 2021 Jun; 37(3):467-472. PubMed ID: 33720447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to coronavirus 2019 in Veterans Health Administration facilities participating in an implementation initiative to enhance access to medication for opioid use disorder.
    Gustavson AM; Gordon AJ; Kenny ME; McHenry H; Gronek J; Ackland PE; Hagedorn HJ
    Subst Abus; 2020; 41(4):413-418. PubMed ID: 32936695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic.
    Frost MC; Zhang L; Kim HM; Lin LA
    JAMA Netw Open; 2022 Oct; 5(10):e2236298. PubMed ID: 36223118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
    Nunes EV; Levin FR; Reilly MP; El-Bassel N
    J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining and supporting high-quality telehealth for patients with opioid use disorder: The promise and potential pitfalls of telehealth expansion.
    Frank CJ; Lin LA
    Subst Abus; 2022; 43(1):1370-1373. PubMed ID: 36222798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender differences in receipt of telehealth versus in person behavioral therapy, medication for opioid use disorder (MOUD), and 90-day MOUD retention during the pandemic: A retrospective veteran cohort study.
    Livingston NA; Sarpong A; Sistad R; Roth C; Banducci AN; Simpson T; Hyde J; Davenport M; Weisberg R
    J Subst Use Addict Treat; 2024 Jan; 156():209188. PubMed ID: 37866437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.